Larson Financial Group LLC Buys 2,193 Shares of Danaher Co. (NYSE:DHR)

Larson Financial Group LLC increased its stake in shares of Danaher Co. (NYSE:DHR) by 761.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,481 shares of the conglomerate’s stock after acquiring an additional 2,193 shares during the period. Larson Financial Group LLC’s holdings in Danaher were worth $574,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of DHR. Nicholas Hoffman & Company LLC. boosted its position in Danaher by 2.3% during the fourth quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after acquiring an additional 43 shares during the last quarter. Drive Wealth Management LLC lifted its stake in shares of Danaher by 3.1% in the 4th quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock valued at $344,000 after purchasing an additional 44 shares during the period. Trust Investment Advisors boosted its position in shares of Danaher by 1.8% during the 4th quarter. Trust Investment Advisors now owns 2,811 shares of the conglomerate’s stock valued at $650,000 after purchasing an additional 49 shares in the last quarter. Connolly Sarah T. increased its holdings in Danaher by 0.5% in the third quarter. Connolly Sarah T. now owns 9,599 shares of the conglomerate’s stock worth $2,382,000 after purchasing an additional 50 shares in the last quarter. Finally, Austin Private Wealth LLC lifted its stake in Danaher by 3.4% in the third quarter. Austin Private Wealth LLC now owns 1,566 shares of the conglomerate’s stock valued at $389,000 after buying an additional 51 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Royal Bank of Canada increased their target price on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Citigroup raised their target price on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Barclays upped their price target on Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 10th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, HSBC upgraded Danaher from a “hold” rating to a “buy” rating and increased their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus target price of $268.00.

Danaher Stock Up 7.2 %

DHR opened at $253.11 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. The firm has a market capitalization of $187.44 billion, a P/E ratio of 39.61, a PEG ratio of 3.96 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00. The company’s 50-day moving average is $248.95 and its 200 day moving average is $230.64.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.18. The company had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. Danaher’s quarterly revenue was down 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.87 earnings per share. Research analysts expect that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be issued a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s payout ratio is 16.90%.

Insider Activity at Danaher

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Teri List sold 3,289 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,957 shares of company stock worth $8,265,802. 10.90% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.